Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Rating of “Hold” from Brokerages

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) have been assigned an average recommendation of “Hold” from the fifteen research firms that are covering the company, Marketbeat reports. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $106.23.

A number of equities research analysts have issued reports on the company. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.87 on Friday. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies has a 1 year low of $64.09 and a 1 year high of $131.98. The company has a fifty day simple moving average of $129.62 and a 200 day simple moving average of $101.61.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Trading of Intra-Cellular Therapies

Several institutional investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB lifted its position in Intra-Cellular Therapies by 124.3% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 133 shares during the period. M&T Bank Corp raised its stake in shares of Intra-Cellular Therapies by 2.2% in the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 138 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Intra-Cellular Therapies by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 141 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of Intra-Cellular Therapies by 5.3% during the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 150 shares in the last quarter. Finally, Pallas Capital Advisors LLC boosted its position in shares of Intra-Cellular Therapies by 6.4% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 192 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.